Home Medicine Validation of CFTR intronic variants identified during cystic fibrosis population screening by a minigene splicing assay
Article
Licensed
Unlicensed Requires Authentication

Validation of CFTR intronic variants identified during cystic fibrosis population screening by a minigene splicing assay

  • Gianpietro Giorgi , Alberto Casarin , Eva Trevisson , Marta Donà , Matteo Cassina , Claudio Graziano , Luigi Picci , Maurizio Clementi EMAIL logo and Leonardo Salviati EMAIL logo
Published/Copyright: March 9, 2015

Abstract

Background: Cystic fibrosis, caused by mutations of the CFTR gene, is the most common autosomal recessive condition in the European population and there are specific screening programs aimed at investigating healthy carriers. They are usually articulated in two steps: initially individuals are screened with a panel of the 20–50 most common CFTR mutations; the second step is offered to partners of carriers who were found negative at the first test and consists in the analysis of the entire CFTR gene. This strategy provides high sensitivity, however, it often identifies novel variants (especially in introns) of unknown significance. Establishing the pathogenicity of these variants of the CFTR gene is not a simple task.

Methods: We have examined five CFTR intronic variants of unclear significance (c.274-6T>C, c.744-6T>G, c.1117-64G>A, c.2620-26A>G, and c.3468+51C>A) using a functional splicing assay based on hybrid minigenes.

Results: Four out of five variants (including c.2620-26A>G which was previously reported as a possible splice-site mutation) did not alter the correct splicing of the minigene and are likely to be neutral polymorphisms, whereas c.744-6T>G caused complete skipping of CFTR exon 7 and should be therefore regarded as a pathogenic CFTR mutation.

Conclusions: Hybrid minigenes assay are a simple and rapid tool to evaluate the effects of intronic variants without the need of analyzing patient’s mRNA, and are particularly suited to analyze variants identified during population screenings.


Corresponding authors: Maurizio Clementi and Leonardo Salviati, Clinical Genetics Unit, Department of Woman and Child Health, University of Padua, Via Giustiniani 3 35128, Padua, Italy, Phone: +39 0498211402, Fax: +39 0498217619, E-mail: ; ; and IRP Città della Speranza, Padua, Italy

References

1. Davies JC, Alton EW, Bush A. Cystic fibrosis. Br Med J 2007;335:1255–9.10.1136/bmj.39391.713229.ADSearch in Google Scholar PubMed PubMed Central

2. Castellani C, Picci L, Tamanini A, Girardi P, Rizzotti P, Assael BM. Association between carrier screening and incidence of cystic fibrosis. J Am Med Assoc 2009;302:2573–9.10.1001/jama.2009.1758Search in Google Scholar PubMed

3. Gasparini P, Marigo C, Bisceglia G, Nicolis E, Zelante L, Bombieri C, et al. Screening of 62 mutations in a cohort of cystic fibrosis patients from north eastern Italy: their incidence and clinical features of defined genotypes. Hum Mutat 1993;2:389–94.10.1002/humu.1380020511Search in Google Scholar PubMed

4. Picci L, Cameran M, Marangon O, Marzenta D, Ferrari S, Frigo AC, et al. A 10-year large-scale cystic fibrosis carrier screening in the Italian population. J Cyst Fibros 2010;9:29–35.10.1016/j.jcf.2009.10.003Search in Google Scholar PubMed

5. Tzetis M, Kanavakis E, Antoniadi T, Doudounakis S, Adam G, Kattamis C. Characterization of more than 85% of cystic fibrosis alleles in the Greek population, including five novel mutations. Hum Genet 1997;99:121–5.Search in Google Scholar

6. Boaretto F, Vettori A, Casarin A, Vazza G, Muglia M, Rossetto MG, et al. Severe CMT type 2 with fatal encephalopathy associated with a novel MFN2 splicing mutation. Neurology 2010;74: 1919–21.10.1212/WNL.0b013e3181e240f9Search in Google Scholar PubMed

7. Salviati L, Trevisson E, Baldoin MC, Toldo I, Sartori S, Calderone M, et al. A novel deletion in the GJA12 gene causes Pelizaeus-Merzbacher-like disease. Neurogenetics 2007;8:57–60.10.1007/s10048-006-0065-xSearch in Google Scholar PubMed

8. Trevisson E, Forzan M, Salviati L, Clementi M. Neurofibromatosis type 1 in two siblings due to maternal germline mosaicism. Clin Genet 2014;85:386–9.10.1111/cge.12177Search in Google Scholar PubMed

9. Cartegni L, Chew SL, Krainer AR. Listening to silence and understanding nonsense: exonic mutations that affect splicing. Nat Rev Genet 2002;3:285–98.10.1038/nrg775Search in Google Scholar PubMed

10. Dorfman R, Nalpathamkalam T, Taylor C, Gonska T, Keenan K, Yuan XW, et al. Do common in silico tools predict the clinical consequences of amino-acid substitutions in the CFTR gene? Clin Genet 2010;77:464–73.10.1111/j.1399-0004.2009.01351.xSearch in Google Scholar PubMed

11. Jian X, Boerwinkle E, Liu X. In silico tools for splicing defect prediction: a survey from the viewpoint of end users. Genet Med 2014;16:497–503.10.1038/gim.2013.176Search in Google Scholar PubMed PubMed Central

12. Forzan M, Salviati L, Pertegato V, Casarin A, Bruson A, Trevisson E, et al. Is CFTR 621+3 A>G a cystic fibrosis causing mutation? J Hum Genet 2010;55:23–6.10.1038/jhg.2009.115Search in Google Scholar PubMed

13. Zielenski J, Bozon D, Markiewicz D, Aubin G, Simard F, Rommens JM, et al. Analysis of CFTR transcripts in nasal epithelial cells and lymphoblasts of a cystic fibrosis patient with 621 + 1G-->T and 711 + 1G-->T mutations. Hum Mol Genet 1993;2:683–7.10.1093/hmg/2.6.683Search in Google Scholar PubMed

14. Pagani F, Stuani C, Zuccato E, Kornblihtt AR, Baralle FE. Promoter architecture modulates CFTR exon 9 skipping. J Biol Chem 2003;278:1511–7.10.1074/jbc.M209676200Search in Google Scholar PubMed

15. Steffensen AY, Dandanell M, Jonson L, Ejlertsen B, Gerdes AM, Nielsen FC, et al. Functional characterization of BRCA1 gene variants by mini-gene splicing assay. Eur J Hum Genet 2014;22:1362–8.10.1038/ejhg.2014.40Search in Google Scholar PubMed PubMed Central

Received: 2014-10-24
Accepted: 2015-1-27
Published Online: 2015-3-9
Published in Print: 2015-10-1

©2015 by De Gruyter

Articles in the same Issue

  1. Frontmatter
  2. Editorials
  3. Laboratory medicine does matter in science (and medicine)… yet many seem to ignore it
  4. The standardization of the urine albumin assays: no longer deferrable
  5. Reviews
  6. The role of telomeres and vitamin D in cellular aging and age-related diseases
  7. Atypical hemolytic uremic syndrome: from diagnosis to treatment
  8. Clinical relevance and contemporary methods for counting blood cells in body fluids suspected of inflammatory disease
  9. EFLM Opinion Paper
  10. How to assess the quality of your analytical method?
  11. Genetics and Molecular Diagnostics
  12. Validation of CFTR intronic variants identified during cystic fibrosis population screening by a minigene splicing assay
  13. General Clinical Chemistry and Laboratory Medicine
  14. Uncertainty in measurement for 43 biochemistry, immunoassay, and hemostasis routine analytes evaluated by a method using only external quality assessment data
  15. A study examining the bias of albumin and albumin/creatinine ratio measurements in urine
  16. National survey on appropriateness of clinical biochemistry reporting in China
  17. Potentiometric measurement of urinary iodine concentration in patients with thyroid diseases with and without previous exposure to non-radioactive iodine
  18. Determination of 21-hydroxylase autoantibodies: inter-laboratory concordance in the Euradrenal International Serum Exchange Program
  19. Value of a commercial kit for detecting anti-C1q autoantibodies and correlation with immunological and clinical activity of lupus nephritis
  20. Comparison of the bead-based simultaneous analysis of specific platelet antibodies assay (SASPA) and Pak Lx Luminex technology with the monoclonal antibody immobilization of platelet antigens assay (MAIPA) to detect platelet alloantibodies
  21. Measurement of the inflammatory response in the early postoperative period after hip and knee arthroplasty
  22. Whole blood thromboelastometry profiles in women with preeclampsia
  23. Increased plasma soluble urokinase plasminogen activator receptor levels in systemic sclerosis: possible association with microvascular abnormalities and extent of fibrosis
  24. Reference Values and Biological Variations
  25. Reference ranges of serum bile acids in children and adolescents
  26. Infectious Diseases
  27. Elevated circulating ghrelin, but not peptide YY(3-36) levels, in term neonates with infection
  28. Cardiovascular Diseases
  29. Head-to-head comparison of 10 natriuretic peptide assays
  30. Prognostic role of BNP in children undergoing surgery for congenital heart disease: analysis of prediction models incorporating standard risk factors
  31. Elevations of inflammatory markers PTX3 and sST2 after resuscitation from cardiac arrest are associated with multiple organ dysfunction syndrome and early death
  32. Identification of molecular species of oxidized triglyceride in plasma and its distribution in lipoproteins
  33. A new formula for estimation of low-density lipoprotein cholesterol in an ethnic Chinese population
  34. Letter to the Editors
  35. Laboratory medicine: let’s say it is the mirror of science (and medicine)
  36. The economic burden of hemolysis
  37. Acute effects of conventional and extended hemodialysis and hemodiafiltration on high-sensitivity cardiac troponins
  38. Cuvette carryover with the gentamicin assay on the Beckman AU480 analyser
  39. Comparison study of two commercially available methods for the determination of golimumab and anti-golimumab antibody levels in patients with rheumatic diseases
  40. Automated alkaline-pH electrophoresis followed by densitometry does not correlate with cation-exchange (CE)-HPLC in quantification of HbA2 and variant hemoglobins
  41. Progression from light chain myeloma to secondary plasma cell leukemia accompanied by peripheral blood eosinophilia
  42. Harmonization of results has not been fully achieved for serum immunoglobulin measurements
  43. The risk of macrovascular complications in subjects genotyped for common IL-6 gene and TNF-α gene variants
  44. Comparison of nucleated red blood cell count with four commercial hematological analyzers
  45. Reply to: The risk of macrovascular complications in subjects genotyped for common IL-6 gene and TNF-α gene variants
  46. Congress Abstracts
  47. Congress of Clinical Chemistry and Laboratory Medicine
  48. 47th National Congress of the Italian Society of Clinical Biochemistry and Clinical Molecular Biology (SIBioC – Laboratory Medicine)
  49. 15th EFLM Continuous Postgraduate Course in Clinical Chemistry and Laboratory Medicine
Downloaded on 22.1.2026 from https://www.degruyterbrill.com/document/doi/10.1515/cclm-2014-1047/html
Scroll to top button